Altmeyer Anne sold $19K of CRBP
Altmeyer Anne sold 2,412 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $7.91 on 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the director’s scheduled open-market sale size, price, and post-transaction holdings; no new corporate event is reported.
Market read
This is a routine insider-sale filing; it may marginally affect sentiment but lacks a fundamental trigger.
What to watch
Traders may over-weight insider selling; without changes in guidance, trial results, or financing terms, the signal is likely weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Corbus Pharmaceuticals Holdings, Inc.
Ticker impact
Corbus Pharmaceuticals director Altmeyer Anne filed an open-market sale of 2,412 shares at $7.9137 on 2026-06-10 under a 10b5-1 plan.
Low near-term impact; any effect is likely sentiment-only and quickly absorbed.
The disclosure is a Form 4 insider sale (open-market) explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying company-specific operational/regulatory update.
Market effects
Minimal; single-company director 10b5-1 sale does not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerCorbus Pharmaceuticals Holdings, Inc.
CRBP, subject of the Form 4 insider transaction disclosure.
- directorAltmeyer Anne
Director who sold 2,412 shares under a Rule 10b5-1 plan.
